New investment positions Singapore as key Novartis biologics site
This article was originally published in Scrip
Executive Summary
Novartis will begin construction in the first quarter of next year of a new biologics manufacturing facility in Singapore as part of a planned $500 million expansion program for its production activities in the Asian city-state.